Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. (Nasdaq: ELIO) is a clinical-stage biotechnology company developing novel lymph node-targeted immunotherapies for the treatment of cancer. The company's website is www.elicio.com.

Elicio's core business focuses on advancing cancer immunotherapies that leverage its proprietary Amphiphile (AMP) technology platform, which is designed to deliver immunotherapeutic payloads directly to lymph nodes through reversible interactions with endogenous albumin. This lymph node-targeting approach aims to generate robust T cell responses and durable anti-tumor immunity. The company believes this differentiated mechanism addresses a key limitation of existing cancer immunotherapies—their inability to sufficiently localize to lymph nodes and engage critical immune cells responsible for adaptive immunity.

The company's lead clinical program is ELI-002 7P, a multivalent lymph node-targeted peptide immunotherapy currently in Phase 2 development for adjuvant treatment of mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC). ELI-002 7P targets seven common KRAS mutations present in approximately 88 percent of PDAC patients and 25 percent of all solid tumors. The formulation is designed as an off-the-shelf therapeutic, eliminating manufacturing delays and costs associated with personalized immunotherapy approaches. Phase 1 data demonstrated strong immunogenicity with 84 percent of patients generating mKRAS-specific T cell responses and encouraging clinical outcomes including median overall survival of 28.9 months in the full study population.

Elicio's preclinical pipeline includes ELI-007, targeting mutant BRAF-driven cancers, and ELI-008, targeting mutant TP53-expressing cancers. Both programs employ the AMP technology platform to target common tumor neoantigens. The company has also demonstrated preclinical applications of its AMP platform in combination with CAR-T cell therapy, TCR-T cell therapy, and as an intratumoral immunomodulator.

The company operates under an exclusive worldwide license agreement with Massachusetts Institute of Technology covering the AMP technology and related patent rights. Elicio is classified as a smaller reporting company and is not a well-known seasoned issuer.